Microbot Medical Inc.
DB:CY9D Stock Report
Microbot Medical Past Earnings Performance Microbot Medical's earnings have been declining at an average annual rate of -9.6%, while the Medical Equipment industry saw earnings declining at 1.1% annually.
Key information
-9.6%
Earnings growth rate
Medical Equipment Industry Growth 4.3% Revenue growth rate n/a Return on equity -172.4% Net Margin n/a Last Earnings Update 30 Jun 2024
Recent past performance updates
Show all updates
Microbot Medical Inc., Annual General Meeting, Dec 17, 2024 Nov 07
Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial Oct 15
Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market Oct 14
Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System Sep 17
Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center Jul 18
Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial Jul 08 Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million. Jul 02
Microbot Medical Inc. announced that it has received $1.762502 million in funding Jun 21
New major risk - Shareholder dilution Jun 06 Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million. Jun 06
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.
New major risk - Share price stability Jun 03
Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health Apr 30
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US Feb 06
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters Jan 30
New major risk - Shareholder dilution Jan 24
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study Jan 19
Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met Dec 29
Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study Dec 07
Microbot Medical Inc. Announces Executive Changes Nov 22
Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process Nov 15
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study Nov 01 Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company Oct 20
Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System Oct 18
Microbot Medical Inc., Annual General Meeting, Nov 02, 2023 Sep 06
Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board Aug 11
Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office Jun 23
New major risk - Shareholder dilution Jun 08
Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System Jun 03
LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process Jun 01
Microbot Medical Inc. announced delayed 10-Q filing May 17
Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System May 10
Microbot Medical Inc. Announces Final Data from Its Recent Animal Study May 06
Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization May 04
Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel Dec 10
Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance Nov 19
High number of new directors Nov 16
Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System Nov 04
Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board Nov 01
Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System Oct 19
Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System Oct 14
Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System Oct 12
Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop. Oct 08
Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment Oct 06
Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board Sep 20
Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board Sep 16
Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System Sep 13
Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board Sep 09
Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System Sep 07
Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month Sep 03
Microbot Medical Inc., Annual General Meeting, Sep 21, 2022 Aug 09
High number of new directors Apr 27
High number of new directors Apr 15
Microbot Medical Inc. Announces Executive Changes Apr 07
Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States Dec 24
Microbot Medical Inc. Secures Patent Allowance in China and Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology Jun 30
New 90-day high: €8.75 Feb 18
Microbot Medical Announces Successful Outcome of Its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt Jan 29
New 90-day high: €7.00 Jan 26
Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with Liberty Robotic System Jan 15
New 90-day low: €5.55 Dec 31
Microbot Medical Inc. Announces Successful Animal Study Utilizing Its Liberty™ Robotic System Sep 17
New 90-day low - €5.40 Sep 04
New 90-day high - €6.90 Aug 15
Revenue & Expenses Breakdown
How Microbot Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History DB:CY9D Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Jun 24 0 -10 4 5 31 Mar 24 0 -10 4 5 31 Dec 23 0 -11 4 6 30 Sep 23 0 -11 5 6 30 Jun 23 0 -12 5 7 31 Mar 23 0 -13 6 7 31 Dec 22 0 -13 6 8 30 Sep 22 0 -14 6 8 30 Jun 22 0 -13 6 7 31 Mar 22 0 -12 6 7 31 Dec 21 0 -11 5 6 30 Sep 21 0 -10 5 5 30 Jun 21 0 -10 6 4 31 Mar 21 0 -9 6 4 31 Dec 20 0 -9 6 3 30 Sep 20 0 -8 5 3 30 Jun 20 0 -8 5 3 31 Mar 20 0 -7 5 3 31 Dec 19 0 -7 4 3 30 Sep 19 0 -8 5 3 30 Jun 19 0 -7 5 3 31 Mar 19 0 -8 5 2 31 Dec 18 0 -7 5 2 30 Sep 18 0 -7 5 2 30 Jun 18 0 -6 4 2 31 Mar 18 0 -8 4 1 31 Dec 17 0 -8 4 1 30 Sep 17 0 -14 10 1 30 Jun 17 0 -14 11 1 31 Mar 17 0 -11 10 1 31 Dec 16 0 -10 9 1 30 Sep 16 0 -2 1 1 30 Jun 16 0 -1 0 1 31 Mar 16 0 -1 0 1 31 Dec 15 0 -1 0 1 31 Dec 14 0 -1 0 1
Quality Earnings: CY9D is currently unprofitable.
Growing Profit Margin: CY9D is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CY9D is unprofitable, and losses have increased over the past 5 years at a rate of 9.6% per year.
Accelerating Growth: Unable to compare CY9D's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CY9D is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (21%).
Return on Equity
High ROE: CY9D has a negative Return on Equity (-172.35%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}